



# HEPATITIS C - ENROLLMENT

Fax to: 512-490-6515

**PHARMACY LOCATION**  
Phone: 512-381-1708  
Toll Free: 855-241-6658  
11209 Metric Blvd., Suite B4  
Austin, TX 78758

DATE: \_\_\_\_\_ **SHIP TO:**  
DATE NEEDED: \_\_\_\_\_  PATIENT  OFFICE

**PATIENT INFO**  
NAME \_\_\_\_\_ E-MAIL \_\_\_\_\_ DOB \_\_\_\_\_  MALE  FEMALE  
ADDRESS \_\_\_\_\_ CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_  
HOME TELEPHONE \_\_\_\_\_ MOBILE PHONE \_\_\_\_\_ SS# \_\_\_\_\_

PLEASE FAX COPY OF INSURANCE CARD (FRONT & BACK) . . . . . **PRESCRIPTION INFORMATION** . . . . .

## DIAGNOSIS CODE (ICD-10)

Date of Diagnosis \_\_\_\_\_  
 B18.2 Chronic Hepatitis C Virus (HCV)  
 Other \_\_\_\_\_

## CLINICAL INFORMATION

Weight \_\_\_\_\_ kg/lb  
Height \_\_\_\_\_ cm/in  
Allergies \_\_\_\_\_  NKDA  
Genotype:  1  2  3  4  5  6  
Subtype:  a  b  a/b  NA  
Cirrhosis:  Y  N  
If Y:  Compensated  Decompensated  
Liver Fibrosis:  F0  F1  F2  F3  F4  
Post Liver Transplant:  Y  N  
 Baseline HCV RNA \_\_\_\_\_ IU/ml  
Date of Lab \_\_\_\_\_  
Co-Infection status:  HIV  HBV  N/A  
Treatment Naïve:  Y  N  
If No:  
Prior HCV Treatment:  
Dates: \_\_\_\_\_ Drug Name \_\_\_\_\_  
Duration of Treatment \_\_\_\_\_  
 Incomplete  Partial  
 Non-Response  Relapse  
Dates: \_\_\_\_\_ Drug Name \_\_\_\_\_  
Duration of Treatment \_\_\_\_\_  
 Incomplete  Partial  
 Non-Response  Relapse  
Expected Duration of Therapy  
 8 Weeks  12 Weeks  
 16 Weeks  24 Weeks

## EPCLUSA®

**EPCLUSA®** (sofosbuvir and velpatasvir)  
400mg /100mg Tablet  
**Directions:**  
 Take 1 tablet PO QD with or without food  
**Qty:**  28 **Refills:**  \_\_\_\_\_

## EPCLUSA® PEDIATRIC

**EPCLUSA®** 200mg /50mg Tablet  
**Directions:**  
 Take 1 tablet PO QD with or without food  
**Qty:**  28 **Refills:**  \_\_\_\_\_

## HARVONI®

**HARVONI®** (ledipasvir and sofosbuvir)  
90/400mg Tablet  
**Directions:**  
 Take 1 tablet PO QD with or without food  
**Qty:**  28 **Refills:**  \_\_\_\_\_

## HARVONI® PEDIATRIC

**HARVONI®**  90/400 mg Tablet  
 45/200 mg Pellet  33.75/150mg Pellet  
**Directions:**  
 Take 1 tablet PO QD with or without food  
 Take the contents of 1 packet PO QD with or without food  
**Qty:**  28 Tablets  28 Pellet Packets  
**Refills:**  \_\_\_\_\_

## MAVYRET™

**MAVYRET™** 100mg/40mg Tablet  
**Directions:**  Take 3 tablets PO QD with food.  
**Qty:**  84 Tablets **Refills:**  \_\_\_\_\_

## MAVYRET™ PEDIATRIC

**MAVYRET™**  
 100/40 mg Tablet  50/20 mg Pellet  
**Directions:**  Take 3 tablets PO QD with food  
 Take the contents of \_\_\_\_\_ packets PO QD with food  
**Qty:**  1 month supply **Refills:**  \_\_\_\_\_

## SOVALDI®

**SOVALDI™** 400mg Tablet  
**Directions:**  Take 1 tablet PO QD with or without food  
**Qty:**  \_\_\_\_\_ **Refills:**  \_\_\_\_\_

## VOSEVI™

**VOSEVI™**  
400mg /100mg / 100mg Tablet  
**Directions:**  
 Take 1 tablet PO QD with food  
**Qty:**  28 **Refills:**  \_\_\_\_\_

## ZEPATIER™

**ZEPATIER™** 50/100 mg Tablet  
**Directions:**  
 Take 1 tablet PO QD with or without food  
**Qty:**  28 **Refills:**  \_\_\_\_\_  
NS5A polymorphism present  Y  N

## RIBAVIRIN

**RIBAVIRIN:**  
 200mg Capsule  200mg Tablet  
**Directions:**  
 Take \_\_\_\_\_ tabs/caps PO q am and \_\_\_\_\_ tabs/caps q pm for a total of \_\_\_\_\_ mg daily with food.  
**Qty:**  \_\_\_\_\_ Tablets / Capsules  
**Refills:**  \_\_\_\_\_

## XIFAXAN®

**XIFAXAN®:**  550mg  
**Directions:**  Take 1 Tab PO BID  
**Qty:**  60 **Refills:**  \_\_\_\_\_

## OTHER

\_\_\_\_\_  
**Directions:**  \_\_\_\_\_  
**Qty:**  \_\_\_\_\_ **Refills:**  \_\_\_\_\_

**PRESCRIBER INFORMATION**  
Prescriber's Name: \_\_\_\_\_ Contact Person: \_\_\_\_\_  
Telephone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_  
Office Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ TAX ID #: \_\_\_\_\_ Medicaid Provider #: \_\_\_\_\_

PRESCRIBER'S SIGNATURE \_\_\_\_\_ (DATE) \*IF BRAND DRUGS ARE PREFERRED, HANDWRITE "BRAND MEDICALLY NECESSARY" ABOVE  
I authorize the Pharmacy noted above and its representatives to act as an agent to initiate and execute the insurance prior authorization process. ©Encore, LP All rights Reserved